IRA – Istituto Ricerche Applicate is a Supporting Partner of MDG 2025, the leading event for the medical device industry organized by Complife Group. Since 1983, the company has supported the market with research, development, and production, placing quality, safety, and compliance at the center of its mission.

About IRA – Istituto Ricerche Applicate

Founded in 1983, IRA is an Italian company specializing in research, development, and contract manufacturing of medical devices, dermocosmetic products, and food supplements. For over forty years, IRA has combined scientific expertise, industrial capability, and regulatory oversight, managing the entire product life cycle — from the initial idea to market release.

The company operates with a strong focus on safety, performance, and technical documentation, supported by structured internal processes for clinical evaluation and risk management.

IRA provides integrated operational support for contract manufacturing of medical devices, including technology transfer, design and optimization of production processes, and the development of dedicated control methods. The company’s approach ensures comprehensive supply chain management — from supplier sourcing and qualification to final product release — guaranteeing full compliance with applicable quality standards and regulatory requirements.

Its mission is clear: to transform research into reliable, market-ready solutions, supporting companies throughout the development process with a scientific and pragmatic approach. IRA’s vision is to be recognized as a national and international benchmark for applied innovation, providing analytical and technological tools that help businesses anticipate future challenges and turn them into competitive advantages.

“Since 1983, being one step ahead for us means investing in quality and responding innovatively to people’s needs. Our mission is to imagine new scenarios and make them possible.”
(from IRA’s official website)

 

The Partnership with MDG 2025 – Supporting Partner

IRA is a strategic partner that turns scientific knowledge into immediately applicable solutions.

The partnership with MDG – MedGenerAction 2025 stems from the sharing of fundamental values: the pursuit of excellence, trust in innovation as a driver of progress, and a long-term ethical commitment to sustainable impact. Both organizations promote a culture of safe, traceable, and compliant products, creating a bridge between research, regulatory affairs, and industry.

In an edition dedicated to innovation, digitalization, and sustainability, IRA brings to MDG 2025 its most tangible contributions:

  • Expertise in CE-marked devices

  • Strong regulatory competence

  • A rigorous approach to compliance and risk management

All elements that make IRA an ideal ally for companies aiming to grow in full compliance with regulations while maintaining controlled development timelines.

Being a Supporting Partner of MDG 2025 allows IRA to reaffirm a principle that has always guided its work: the synergy between research and application is the key to building the future of the medical sector.

Companies interested in developing or industrializing medical devices with a rigorous compliance-oriented approach can rely on IRA’s experience and methodology.

(For information or joint projects, companies can contact the IRA Group to explore dedicated pathways for the industrialization and production of medical devices, with specialized technical support focused on CE marking readiness and subsequent market launch.)

Sponsored content created in collaboration with the Supporting Partner